The chemical class known as COL20A1 inhibitors comprises a diverse set of compounds strategically designed to modulate specific signaling pathways and cellular processes indirectly influencing COL20A1 expression. Among these, SB431542 acts as a TGF-β receptor inhibitor, disrupting the SMAD pathway and subsequently altering downstream signaling events that indirectly impact COL20A1 expression. U0126, a MEK1/2 inhibitor, targets the MAPK pathway, leading to the modulation of signaling cascades that influence COL20A1 expression and function. In addition, SP600125, a JNK inhibitor, affects the JNK pathway, thereby altering intracellular signaling and indirectly influencing COL20A1 expression and regulation. Wortmannin, a PI3K inhibitor, impacts the PI3K/AKT pathway, modulating downstream signals and indirectly influencing COL20A1 expression. Rapamycin, an mTOR inhibitor, indirectly modulates COL20A1 expression by altering key signaling events within the mTOR pathway.
Furthermore, LY294002, a PI3K/AKT inhibitor, disrupts the PI3K/AKT pathway, leading to changes in intracellular signaling that indirectly influence COL20A1 expression. PD98059, a MEK1 inhibitor, targets the MAPK pathway, modulating signaling cascades and indirectly impacting COL20A1 expression and function. SB203580, a p38 MAPK inhibitor, alters intracellular signaling, indirectly influencing COL20A1 expression. The chemical class also includes SP2509, an EZH2 inhibitor, which impacts the epigenetic regulation of gene expression and indirectly modulates COL20A1 expression through epigenetic changes. Trametinib, a MEK inhibitor, targets the MAPK pathway, leading to the modulation of signaling cascades that indirectly influence COL20A1 expression and function. GSK-J4, a JMJD3 inhibitor, affects epigenetic regulation, modulating gene expression and indirectly influencing COL20A1 through epigenetic mechanisms. Lastly, AG490, a JAK2 inhibitor, impacts the JAK/STAT pathway, altering intracellular signaling and indirectly influencing COL20A1 expression.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
TGF-β receptor inhibitor impacting the SMAD pathway. Alters downstream signaling, indirectly influencing COL20A1 expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting the JNK pathway. Alters intracellular signaling, indirectly influencing COL20A1 expression and regulation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor impacting the PI3K/AKT pathway. Modulates downstream signals, indirectly influencing COL20A1 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor affecting the mTOR pathway. Indirectly modulates COL20A1 expression by altering key signaling events. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K/AKT inhibitor impacting the PI3K/AKT pathway. Alters intracellular signaling, indirectly influencing COL20A1 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK1 inhibitor targeting the MAPK pathway. Modulates signaling cascades, indirectly impacting COL20A1 expression and function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor affecting the p38 MAPK pathway. Alters intracellular signaling, indirectly influencing COL20A1 expression. | ||||||
SP2509 | 1423715-09-6 | sc-492604 | 5 mg | $284.00 | ||
EZH2 inhibitor impacting the epigenetic regulation of gene expression. Indirectly modulates COL20A1 expression through epigenetic changes. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
MEK inhibitor targeting the MAPK pathway. Modulates signaling cascades, indirectly impacting COL20A1 expression and function. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
JMJD3 inhibitor affecting epigenetic regulation. Modulates gene expression, indirectly influencing COL20A1 through epigenetic mechanisms. | ||||||